Our antiviral pipeline is characterized by novel targets discovered by exploiting the dependency of viruses on hosts. We are generating a new class of antiviral agents designed to have broad-spectrum antiviral activity and high barrier to resistance. 3-V is currently developing antiviral therapeutic candidates for respiratory syncytial virus (RSV), cytomegalovirus (CMV) and other important human pathogens.

We utilize an integrated discovery approach that harnesses rigorous, innovative science coupled with best practices honed through years of experience in drug discovery and development. 3-V’s platform has produced a series of targets in virology and oncology. To date, our discovery efforts have resulted in programs with multiple potential indications from a single discovery.